共 50 条
Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors
被引:9
|作者:
Shida, Yoichi
[1
]
Nakazawa, Tsutomu
[1
,2
]
Matsuda, Ryosuke
[1
]
Morimoto, Takayuki
[1
]
Nishimura, Fumihiko
[1
]
Nakamura, Mitsutoshi
[1
,3
]
Maeoka, Ryosuke
[1
]
Yamada, Shuichi
[1
]
Nakagawa, Ichiro
[1
]
Park, Young-Soo
[1
]
Yasukawa, Motoaki
[4
,5
]
Tojo, Takashi
[4
,6
]
Tsujimura, Takahiro
[3
]
Nakase, Hiroyuki
[1
]
机构:
[1] Nara Med Univ, Dept Neurosurg, Kashihara, Nara 6348521, Japan
[2] Grandsoul Res Inst Immunol Inc, Uda, Nara 6332221, Japan
[3] Clin Grandsoul Nara, Uda, Nara 6332221, Japan
[4] Nara Med Univ, Dept Thorac Surg, Kashihara, Nara 6348521, Japan
[5] Osaka Kaisei Hosp, Dept Surg, Yodogawa, Osaka 5320003, Japan
[6] Saiseikai Chuwa Hosp, Dept Thorac Surg, Sakurai, Nara 6330054, Japan
关键词:
PD-1;
PD-L1;
NK cell;
glioblastoma;
NEWLY-DIAGNOSED GLIOBLASTOMA;
DELTA-T CELLS;
ADJUVANT TEMOZOLOMIDE;
PD-L1;
EXPRESSION;
NK CELLS;
IMMUNOTHERAPY;
THERAPY;
RADIOTHERAPY;
CONCOMITANT;
PATTERNS;
D O I:
10.3390/ijms22189975
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Glioblastoma (GBM) is the leading malignant intracranial tumor and is associated with a poor prognosis. Highly purified, activated natural killer (NK) cells, designated as genuine induced NK cells (GiNKs), represent a promising immunotherapy for GBM. We evaluated the anti-tumor effect of GiNKs in association with the programmed death 1(PD-1)/PD-ligand 1 (PD-L1) immune checkpoint pathway. We determined the level of PD-1 expression, a receptor known to down-regulate the immune response against malignancy, on GiNKs. PD-L1 expression on glioma cell lines (GBM-like cell line U87MG, and GBM cell line T98G) was also determined. To evaluate the anti-tumor activity of GiNKs in vivo, we used a xenograft model of subcutaneously implanted U87MG cells in immunocompromised NOG mice. The GiNKs expressed very low levels of PD-1. Although PD-L1 was expressed on U87MG and T98G cells, the expression levels were highly variable. Our xenograft model revealed that the retro-orbital administration of GiNKs and interleukin-2 (IL-2) prolonged the survival of NOG mice bearing subcutaneous U87MG-derived tumors. PD-1 blocking antibodies did not have an additive effect with GiNKs for prolonging survival. GiNKs may represent a promising cell-based immunotherapy for patients with GBM and are minimally affected by the PD-1/PD-L1 immune evasion axis in GBM.
引用
收藏
页数:14
相关论文